{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:37:48Z","timestamp":1792075068721,"version":"4.4.0"},"reference-count":84,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Methicillin-resistant Staphylococcus aureus (MRSA) represents a major therapeutic challenge due to its multidrug-resistance and the associated clinical burden. Daptomycin (DAP), a cyclic lipopeptide antibiotic, has become a key agent for the treatment of severe MRSA infections owing to its rapid bactericidal activity and favourable safety profile. In this narrative review, we examine studies published between 2010 and April 2025. The data suggest that treatment with high-dose (8\u201310 mg kg\u207b1) DAP shortened the time to blood-culture sterilisation by a median of 2 days compared with standard-dose vancomycin without increasing toxicity when model-informed area-under-the-curve monitoring was employed. Particular attention is given to the synergistic effects of DAP combined with fosfomycin or \u03b2-lactams, especially ceftaroline and ceftobiprole, in overcoming persistent and refractory MRSA infections; this approach results in a reduction in microbiological failure relative to monotherapy. Resistance remains uncommon (&lt;2% of isolates), but recurrent mutations in mprF, liaFSR, and walK underscore the need for proactive genomic surveillance. Despite promising preclinical and clinical evidence supporting combination strategies, further randomized controlled trials are necessary to establish their definitive role in clinical practice, as are head-to-head cost-effectiveness evaluations. DAP remains a critical option in the evolving landscape of MRSA management, provided its use is integrated with precision dosing, resistance surveillance, and antimicrobial-stewardship frameworks.<\/jats:p>","DOI":"10.3390\/antibiotics14060617","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:38:15Z","timestamp":1750232295000},"page":"617","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Use of Daptomycin to Manage Severe MRSA Infections in Humans"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-0229","authenticated-orcid":false,"given":"Marco","family":"Fiore","sequence":"first","affiliation":[{"name":"Department of Women, Child and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-5968","authenticated-orcid":false,"given":"Aniello","family":"Alfieri","sequence":"additional","affiliation":[{"name":"Department of Women, Child and General and Specialized Surgery, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"},{"name":"Department of Elective Surgery, Postoperative Intensive Care Unit and Hyperbaric Oxygen Therapy, A.O.R.N. Antonio Cardarelli, V.le Antonio Cardarelli 9, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0480-431X","authenticated-orcid":false,"given":"Daniela","family":"Fiore","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care Unit, ASUR Marche, Area Vasta n. 4, Via Murri, 63023 Fermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6004-3052","authenticated-orcid":false,"given":"Pasquale","family":"Iuliano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases Section, San Giuseppe Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"Spatola","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases Section, San Giuseppe Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy"},{"name":"Department of Mental Health and Public Medicine, Infectious Diseases Section, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3388-8560","authenticated-orcid":false,"given":"Andrea","family":"Limone","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases Section, San Giuseppe Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy"},{"name":"Department of Mental Health and Public Medicine, Infectious Diseases Section, University of Campania \u201cL. Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pezone","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, \u201cSan Giuseppe Moscati\u201d Hospital, 81031 Aversa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-4101","authenticated-orcid":false,"given":"Sebastiano","family":"Leone","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases Section, San Giuseppe Moscati Hospital, Contrada Amoretta, 83100 Avellino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijid.2010.05.003","article-title":"Methicillin-resistant Staphylococcus aureus: The superbug","volume":"14","author":"Ippolito","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrmicro2200","article-title":"Waves of resistance: Staphylococcus aureus in the antibiotic era","volume":"7","author":"Chambers","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14656566.2024.2367003","article-title":"Pharmacotherapies for multidrug-resistant gram-positive infections: Current options and beyond","volume":"25","author":"Leone","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","article-title":"Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus","volume":"47","author":"Silverman","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1086\/367653","article-title":"Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection","volume":"36","author":"Engemann","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13756-024-01383-8","article-title":"Comparison of disease and economic burden between MRSA infection and MRSA colonization in a university hospital: A retrospective data integration study","volume":"13","author":"Hirabayashi","year":"2024","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e20170183","DOI":"10.1542\/peds.2017-0183","article-title":"Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children","volume":"139","author":"Hamdy","year":"2017","journal-title":"Pediatrics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3947\/ic.2013.45.2.202","article-title":"Impact of Methicillin-Resistance on Mortality in Children and Neonates with Staphylococcus aureus Bacteremia: A Meta-analysis","volume":"45","author":"Park","year":"2013","journal-title":"Infect. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/649797","article-title":"Clinical and economic impact of methicillin-resistant Staphylococcus aureus colonization or infection on neonates in intensive care units","volume":"31","author":"Song","year":"2010","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5694\/j.1326-5377.2001.tb143562.x","article-title":"Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: A meta-analysis","volume":"175","author":"Whitby","year":"2001","journal-title":"Med. J. Aust."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: A systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","first-page":"47","article-title":"Daptomycin: An evidence-based review of its role in the treatment of Gram-positive infections","volume":"9","author":"Seaton","year":"2016","journal-title":"Infect. Drug Resist."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections","volume":"55","author":"Steenbergen","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.2147\/IDR.S272733","article-title":"Methicillin-Resistant Staphylococcus aureus (MRSA): One Health Perspective Approach to the Bacterium Epidemiology, Virulence Factors, Antibiotic-Resistance, and Zoonotic Impact","volume":"13","author":"Algammal","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.00350-06","article-title":"Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm","volume":"51","author":"Raad","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Boutet-Dubois, A., Magnan, C., Lienard, A., Pouget, C., Bouchet, F., Marchandin, H., Larcher, R., Lavigne, J.P., and Pantel, A. (2023). In Vivo-Acquired Resistance to Daptomycin during Methicillin-Resistant Staphylococcus aureus Bacteremia. Antibiotics, 12.","DOI":"10.3390\/antibiotics12121647"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/JCM.41.1.5-14.2003","article-title":"Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus","volume":"41","author":"Cui","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1128\/AAC.01184-13","article-title":"Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance","volume":"57","author":"Yang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2012.06819.x","article-title":"Mechanisms of daptomycin resistance in Staphylococcus aureus: Role of the cell membrane and cell wall","volume":"1277","author":"Bayer","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1128\/AAC.00970-15","article-title":"Frequency and Distribution of Single-Nucleotide Polymorphisms within mprF in Methicillin-Resistant Staphylococcus aureus Clinical Isolates and Their Role in Cross-Resistance to Daptomycin and Host Defense Antimicrobial Peptides","volume":"59","author":"Bayer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1128\/AAC.00676-12","article-title":"Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: Influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2015.05.008","article-title":"Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence","volume":"46","author":"Stefani","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/cid\/ciaa1081","article-title":"Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial","volume":"72","author":"Pujol","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","unstructured":"U.S Food and Drug Administration (2025, June 12). Daptomycin for Injection\u2014Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210282s000lbl.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","article-title":"Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(\u00ae) Outcomes Registry and Experience","volume":"32","author":"Seaton","year":"2015","journal-title":"Adv. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40266-013-0114-8","article-title":"Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: An open-label, multicentre, randomized phase IIIb trial","volume":"30","author":"Konychev","year":"2013","journal-title":"Drugs Aging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/phar.1298","article-title":"Safety and effectiveness of daptomycin across a hospitalized obese population: Results of a multicenter investigation in the southeastern United States","volume":"33","author":"Bookstaver","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg\/L: A matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/phar.1220","article-title":"Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"33","author":"Kullar","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","article-title":"Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg\/L: A Multicenter Evaluation","volume":"38","author":"Moise","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00134-014-3571-6","article-title":"Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1093\/cid\/ciaa1572","article-title":"Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients with Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections","volume":"72","author":"Schweizer","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Adamu, Y., Puig-Asensio, M., Dabo, B., and Schweizer, M.L. (2024). Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0293423"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40265-016-0610-3","article-title":"Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients","volume":"76","author":"Pensi","year":"2016","journal-title":"Drugs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijantimicag.2018.03.008","article-title":"Population pharmacokinetics of daptomycin in critically ill patients","volume":"52","author":"Soraluce","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40262-020-00968-x","article-title":"Clinical Pharmacokinetics of Daptomycin","volume":"60","author":"Gregoire","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Heitzmann, J., Thoma, Y., Bricca, R., Gagnieu, M.C., Leclerc, V., Roux, S., Conrad, A., Ferry, T., and Goutelle, S. (2022). Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010114"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/FTD.0000000000001070","article-title":"Evaluation of Limited Sampling Strategies for Bayesian Estimation of Daptomycin Area Under the Concentration-Time Curve: A Short Communication","volume":"45","author":"Tuloup","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106712","DOI":"10.1016\/j.ijantimicag.2023.106712","article-title":"The impact of daptomycin therapeutic drug monitoring on clinical outcomes: A systematic review","volume":"61","author":"Cairns","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.clinthera.2015.11.007","article-title":"Beyond Vancomycin: The Tail of the Lipoglycopeptides","volume":"37","author":"Klinker","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.clinthera.2014.09.005","article-title":"Daptomycin in Combination with Other Antibiotics for the Treatment of Complicated Methicillin-Resistant Staphylococcus aureus Bacteremia","volume":"36","author":"Dhand","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Entenza","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1128\/AAC.01321-15","article-title":"Population Pharmacokinetics of Fosfomycin in Critically Ill Patients","volume":"59","author":"Parker","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jgar.2017.05.022","article-title":"In vitro activity of daptomycin combinations with rifampicin, gentamicin, fosfomycin and fusidic acid against MRSA strains","volume":"10","author":"Aktas","year":"2017","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_59","first-page":"10","article-title":"The Combination of Daptomycin and Fosfomycin Has Synergistic, Potent, and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus in a Rabbit Model of Experimental Endocarditis","volume":"62","author":"Gasch","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e0164921","DOI":"10.1128\/AAC.01649-21","article-title":"Synergy Mechanisms of Daptomycin-Fosfomycin Combinations in Daptomycin-Susceptible and -Resistant Methicillin-Resistant Staphylococcus aureus: In Vitro, Ex Vivo, and In Vivo Metrics","volume":"66","author":"Mishra","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jiac.2023.10.024","article-title":"Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature","volume":"30","author":"Omori","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eimc.2018.05.009","article-title":"Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci","volume":"37","author":"Parra","year":"2019","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/jac\/dku236","article-title":"Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes","volume":"69","author":"Barber","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"107469","DOI":"10.1016\/j.ijantimicag.2025.107469","article-title":"\u201cSeesaw effect\u201d between daptomycin and ceftobiprole in daptomycin-resistant methicillin-resistant Staphylococcus aureus isolates","volume":"65","author":"Chen","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/AAC.00487-10","article-title":"Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the \u201cseesaw effect\u201d)","volume":"54","author":"Yang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/23744235.2016.1277587","article-title":"A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)","volume":"49","author":"Shafiq","year":"2017","journal-title":"Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1128\/AAC.00386-15","article-title":"Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic\/Pharmacodynamic Model","volume":"59","author":"Barber","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"ofz538","DOI":"10.1093\/ofid\/ofz538","article-title":"Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"106310","DOI":"10.1016\/j.ijantimicag.2021.106310","article-title":"Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care","volume":"57","author":"Johnson","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hicks, A.S., Dolan, M.A., Shah, M.D., Elwood, S.E., Platts-Mills, J.A., Madden, G.R., Elliott, Z.S., and Eby, J.C. (2025). Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia. Ann. Clin. Microbiol. Antimicrob., 24.","DOI":"10.1186\/s12941-025-00773-z"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Huang, C., Chen, I., and Lin, L. (2022). Comparing the Outcomes of Ceftaroline plus Vancomycin or Daptomycin Combination Therapy versus Vancomycin or Daptomycin Monotherapy in Adults with Methicillin-Resistant Staphylococcus aureus Bacteremia\u2014A Meta-Analysis. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081104"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/mdr.2020.0350","article-title":"Vancomycin or Daptomycin Plus a \u03b2-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: A Systematic Review and Meta-Analysis","volume":"27","author":"Yi","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciz746","article-title":"Daptomycin Plus \u03b2-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study","volume":"71","author":"Jorgensen","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijantimicag.2016.04.006","article-title":"Meticillin-resistant Staphylococcus aureus endocarditis: First report of daptomycin plus ceftobiprole combination as salvage therapy","volume":"47","author":"Oltolini","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2019.07.020","article-title":"Ceftobiprole for the treatment of infective endocarditis: A case series","volume":"20","author":"Tascini","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1128\/AAC.00088-14","article-title":"Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model of simulated endocardial vegetations","volume":"58","author":"Werth","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e20162477","DOI":"10.1542\/peds.2016-2477","article-title":"Daptomycin for Complicated Skin Infections: A Randomized Trial","volume":"139","author":"Bradley","year":"2017","journal-title":"Pediatrics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000001926","article-title":"Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia","volume":"37","author":"Arrieta","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/INF.0000000000002790","article-title":"Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis","volume":"39","author":"Bradley","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Persha, H., Thacker, S.A., Hornback, K.M., Alvira-Arill, G.R., Lueking, R., and Morrisette, T. (2024). Real-World Clinical Characteristics and Outcomes with Daptomycin Use in Pediatric Patients: A Retrospective Case Series. Antibiotics, 13.","DOI":"10.3390\/antibiotics13090833"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/jcph.2425","article-title":"Daptomycin Dose Optimization in Pediatric Staphylococcus aureus Bacteremia: A Pharmacokinetic\/Pharmacodynamic Investigation","volume":"64","author":"Olney","year":"2024","journal-title":"J. Clin. Pharmacol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/617\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:54:04Z","timestamp":1760032444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":84,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["antibiotics14060617"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14060617","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}